FamiCord Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
707
- Stock Symbol
-
V3V
- Investments
-
13
- Share Price
-
$2.70
- (As of Thursday Closing)
FamiCord General Information
Description
FamiCord AG is an umbilical cord blood bank. It supplies cryopreservation and provides logistics for the collection of blood, preparation, and storage of stem cells from umbilical cord blood and tissue. The company is active in the areas of cell and gene therapies and CDMO. It continues to develop from a pure stem cell bank into a more broadly based cell bank that can supply available patients own cells for current and future cell therapies. Its services include stem cells banking, stem cells scientific proof, FamiCord contribution, stem cell applications list, stem cell applications stories, and stem cells banking for society. Its segments include Subgroup Vita 34 and Subgroup PBKM, which generate maximum revenue. It operates in Germany, Poland, Switzerland, and other foreign countries.
Contact Information
Website
www.famicord.comCorporate Office
- Perlickstrasse 5
- 04103 Leipzig
- Germany
Corporate Office
- Perlickstrasse 5
- 04103 Leipzig
- Germany
FamiCord Stock Performance
As of 12-Nov-2026, FamiCord’s stock price is $2.70. Its current market cap is $47.9M with 17.8M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.70 | $2.68 | $2.61 - $8.23 | $47.9M | 17.8M | 1.32K | -$0.50 |
FamiCord Financials Summary
As of 30-Jun-2026, FamiCord has a trailing 12-month revenue of $102M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 84,356 | 128,763 | 75,100 | 115,199 |
| Revenue | 102,403 | 99,460 | 88,928 | 83,387 |
| EBITDA | 5,246 | 5,826 | 467 | 5,049 |
| Net Income | (8,952) | (7,110) | (13,132) | (2,018) |
| Total Assets | 185,382 | 190,006 | 158,934 | 176,250 |
| Total Debt | 26,295 | 27,611 | 18,831 | 23,849 |
FamiCord Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
FamiCord Patents
FamiCord Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2756754-A1 | Method for the treatment of umbilical cord tissue, in particular associated with the preservation of the tissue | Active | 17-Jan-2013 | ||
| EP-2756754-B1 | Method for the treatment of umbilical cord tissue, in particular associated with the preservation of the tissue | Active | 17-Jan-2013 | ||
| EP-1438088-A2 | Bag system for cryopreservation of body fluids | Active | 22-Oct-2001 | ||
| WO-2003041634-A2 | Bag system for cryopreservation of body fluids | Inactive | 22-Oct-2001 | ||
| WO-2003041634-A3 | Bag system for cryopreservation of body fluids | Inactive | 22-Oct-2001 | A01N1/146 |
FamiCord Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
FamiCord Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
FamiCord Investments & Acquisitions (13)
FamiCord’s most recent deal was a Merger/Acquisition with Cordvida Portugal. The deal was made on 01-May-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cordvida Portugal | 01-May-2026 | Merger/Acquisition | Media and Information Services (B2B) | ||
| Rodinná Banka Perinatálních a Mesenchymálních Buněk | 01-Jun-2025 | Merger/Acquisition | Other Healthcare Services | ||
| FamiCordTx | 02-Feb-2022 | Corporate | Drug Discovery | ||
| Polski Bank Komórek Macierzystych | 15-Nov-2021 | Merger/Acquisition | Other Healthcare Services | ||
| Seracell Pharma | 01-Jul-2017 | Merger/Acquisition | Laboratory Services (Healthcare) |
FamiCord ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
FamiCord Exits (1)
FamiCord’s most recent exit was on 01-Apr-2008 from MukoCell. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| MukoCell | 01-Apr-2008 | Completed |
|
FamiCord Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Stellacure | Hamburg, Germany | 2006 | |
| StemCare | Gentofte, Denmark | 2003 | |
| Seracell Pharma | Rostock, Germany | 2002 | |
| Polski Bank Komórek Macierzystych | Warsaw, Poland | 2002 | |
| Vita 34 (Healthcare Services) | Vienna, Austria | 1997 |
FamiCord FAQs
-
When was FamiCord founded?
FamiCord was founded in 1997.
-
Where is FamiCord headquartered?
FamiCord is headquartered in Leipzig, Germany.
-
What is the size of FamiCord?
FamiCord has 707 total employees.
-
What industry is FamiCord in?
FamiCord’s primary industry is Other Commercial Services.
-
Is FamiCord a private or public company?
FamiCord is a Public company.
-
What is FamiCord’s stock symbol?
The ticker symbol for FamiCord is V3V.
-
What is the current stock price of FamiCord?
As of 12-Nov-2026 the stock price of FamiCord is $2.70.
-
What is the current market cap of FamiCord?
The current market capitalization of FamiCord is $47.9M.
-
What is FamiCord’s current revenue?
The trailing twelve month revenue for FamiCord is $102M.
-
What is FamiCord’s annual earnings per share (EPS)?
FamiCord’s EPS for 12 months was -$0.50.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
